Set-off issue for Bactiguard’s bond loan


On 23 May, 2014 Bactiguard Holding AB (publ) (“Bactiguard” or ”the Company”) announced that holders of the Company’s bonds would be offered* the option to offset their bonds against Bactiguard shares.

The offset offer was made contingent upon the Company’s completion of an IPO on NASDAQ OMX Stockholm. In a previously-issued press release the Company announced its intention to proceed with an IPO in late June 2014.

The acceptance period for the offset offer closed on 3 June 2014. Of the nominal bond amount of SEK 450 million, holders of bonds totaling a nominal amount of SEK 205.5 million elected to offset their bonds against shares. Following completion of the set-off the Company’s interest expense will be reduced by SEK 22.6 million per annum.

"Bactiguard is stronger due to the high acceptance level of the offset offer. At the same time, we are achieving our goal of significantly reducing the company’s interest expense. We look forward to soon taking the next step and offering more people the chance to become Bactiguard shareholders”, says Christian Kinch, Chairman of the Board of Bactiguard.

The purpose of the offset offer is to strengthen the Company’s capital structure and enable future investments and growth.

*The offer involved offsetting bond-holders’ nominal bond claims against Bactiguard, plus interest accrued as at the decision date for the set-off issue, for Bactiguard B-shares at a price corresponding to the introduction rate at time of IPO after applicaiton of a 5 per cent premium to the nominal amount of the bond claims.

Bactiguard Holding AB (publ) is required to disclose the above information under the provisions of the Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8:00 AM CET on 4 June 2014.

Fredrik Järrsten - CFO
+46 725 500 089

Cecilia Edström - Director of Communications
+46 722 262 328

Bactiguard is a Swedish medtech company with a business concept of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company’s patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguard®-coated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of coated catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the EU, Middle East, Asia and South America. The company reported  sales of approximately SEK 130 million in 2013, has 60 employees, headquarters in Stockholm and production facilities in Markaryd and Malaysia. 


About Us

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large. The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract. Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. Recently, Bactiguard completed the acquisition of Malaysian Vigilenz, a manufacturer and supplier of medical devices and consumables, primarily within wound care and infection prevention. Following the acquisition, Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at


Documents & Links